We have previously described a melanoma model harboring the 4-hydroxytamoxifen inducible BRAFV600E mutation and loss of PTEN, under the control of Tyr::CreERT2 [18], a model similar to one described elsewhere [19]. This evidence concerns the gene PTEN and melanoma.